<DOC>
	<DOCNO>NCT01795105</DOCNO>
	<brief_summary>This Post-Marketing Surveillance study Abilify® tablet accordance Korean regulation New Drug Re-examination ( i.e . New Drug Re-examination Standards : KFDA Notification No . 2010-94 date 27 December 2010 ) .</brief_summary>
	<brief_title>ABF Tourette 's Disorder PMS</brief_title>
	<detailed_description>This study conduct prospective , single-arm , multi-center format . As study observational nature , patient 's follow-up prescriptive nature must leave judgment physician ( investigator ) , within period observation set forth protocol .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>Pediatric patient 6 18 year age Tourette 's Disorder Patients prescribe Abilify® treatment per investigator 's medical judgment . Patients give write authorization use personal health data Patients start Abilify® treatment agreement place Patients know hypersensitivity Aripiprazole excipients Abilify® Patients treat Abilify® Patients rare hereditary problem galactose intolerance , lapp lactase deficiency , glucosegalactose malabsorption Patients score 0 ( Not assess ) 1 ( Normal , ill ) TSCGIS Patients participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>